Uppsala, Sweden – July 15, 2013 - Orexo AB today announced the appointment of
Henrik Juuel as the new Executive Vice President and CFO. Henrik Juuel will be a
member of the company’s executive management team, succeeding Carl-Johan
Blomberg, who will leave Orexo as CFO of the company after successful two year
tenure. Carl-Johan will continue to support Orexo and Henrik in a transition
“On behalf of Orexo, I would like to thank Carl-Johan Blomberg for his
engagement and involvement in transforming Orexo in to a commercially focused
company over the past years. He has taken important part in ensuring that Orexo
is financially strong and well prepared to support the launch of Zubsolv” says
Nikolaj Sørensen, President and CEO of Orexo AB.
Orexo is entering a new phase with increasing effort towards commercialization
of the company’s lead product Zubsolv, approved by the FDA earlier this month
for the US market. Henrik Juuel brings extensive relevant experience from senior
international management positions within the life science industry, including
positions as CFO for NNE Pharmaplan and GN Resound.
“Henrik Juuel has an impressive career track, having worked in multiple and
increasingly senior positions within different finance functions in the life
science industry. His experience from financial management of international
commercial operations will be important for the continued success of Orexo AB,
as our company continues expanding” says Nikolaj Sørensen, President and CEO of
Henrik Juuel commented “I am honored to be appointed CFO of Orexo, and I look
forward to closely working with Nikolaj Sørensen to complete the transformation
of Orexo to a commercial company with growing international sales and strong
partnerships. I am excited about the company’s future opportunities and be a
part of the leadership of Orexo.”
For further information, please contact:
Nikolaj Sørensen, President and CEO
Tel: +46 70-350 78 88, E-mail: email@example.com
Orexo is an emerging specialty pharma company with commercial operations in the
United States and R&D in Sweden developing improved treatments using proprietary
drug delivery technology. Orexo’s expertise is within the area of reformulation
technologies and especially sublingual formulations. The company has a portfolio
of revenue-generating US and EU approved products currently marketed under
license and a pipeline of several reformulations of approved compounds for areas
of unmet medical need. Orexo also has collaboration projects with several
international pharmaceutical companies. Orexo, with its headquarters in Sweden,
is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.
For more information about Orexo please visit www.orexo.com.
Orexo is required under the Financial Instruments Trading Act to make the
information in this press release public. The information was submitted for
publication at 08:55 am CET on July 15, 2013.
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.